STOCK PICKS AND PANS

12/7/16

New Stocks on Most Attractive/Most Dangerous: December 2016

Recap from November Picks

Our Most Attractive Stocks (+11.4%) outperformed the S&P 500 (+5.3%) last month. Most Attractive Large Cap stock LaSalle Hotel Properties (LHO) gained 21% and Most Attractive Small Cap stock Sierra Bancorp (BSRR) was up 31%. Overall, 33 out of the 40 Most Attractive stocks outperformed the S&P 500 in November.

Most Dangerous Large Cap stock Netflix (NFLX) fell by 4% and Most Dangerous Small Cap Stock Amedisys Inc. (AMED) fell by 10%. Overall, nine out of the 40 Most Dangerous stocks outperformed the S&P 500 in November.

The successes of the Most Attractive and Most Dangerous stocks highlight the value of our forensic accounting as <u>featured in Barron's</u>. Our research helps clients <u>fulfill fiduciary</u> duties when making investment recommendations.

22 new stocks make our Most Attractive list this month and 20 new stocks fall onto the Most Dangerous list this month. December's Most Attractive and Most Dangerous stocks were made available to members on 12/1/2016.


Our Most Attractive stocks have high and rising returns on invested capital (ROIC) and low <u>price to economic book value ratios.</u> Most Dangerous stocks have <u>misleading earnings</u> and long <u>growth appreciation periods</u> implied by their market valuations.

Most Attractive Stocks Feature for December: Gentex Corporation (GNTX: \$19/share)

Gentex Corporation (GNTX), automobile parts supplier, is one of the additions to our <u>Most Attractive stocks</u> for December. We first featured Gentex in <u>December 2015</u> when it first made our Most Attractive stocks list and despite the stock price rising 19% since the publish date, GNTX remains undervalued.

Gentex has built a highly profitable business supplying automatic-dimming rearview mirrors and electronics to the automotive and aviation markets. Since 2009, Gentex has grown after-tax profit (NOPAT) by an impressive 31% compounded annually, to \$318 million in 2015 and \$353 million over the last twelve months, per Figure 1.

Figure 1: NOPAT Growth Since 2009



Sources: New Constructs, LLC and company filings

Apart from profit growth, Gentex currently earns a top-quintile return on invested capital (ROIC) of 25% and has grown its NOPAT margin from 12% in 2009 to 21% TTM. Over the past five years, Gentex has generated cumulative \$80 million in free cash flow, and currently pays a dividend that yields 1.9%.



Impacts of Footnotes Adjustments and Forensic Accounting

In order to derive the <u>true recurring cash flows</u>, an accurate <u>invested capital</u>, and an accurate shareholder value, we made the following adjustments to Gentex's 2015 10-K:

Income Statement: we made \$9 million of adjustments, with a net effect of removing \$1 million in non-operating income (<1% of revenue). We removed \$5 million in non-operating income and \$4 million in non-operating expenses. You can see all the adjustments made to GNTX's income statement here.

Balance Sheet: we made \$756 million of adjustments to calculate invested capital with a net decrease of \$594 million. The largest adjustment was \$620 million due to excess cash. This adjustment represented 31% of reported net assets. You can see all the adjustments made to GNTX's balance sheet here.

Valuation: we made \$1 billion of adjustments with a net effect of increasing shareholder value by \$389 million. Apart from the excess cash noted above, one of the notable adjustments was the removal of \$76 million due to outstanding employee stock options. This adjustment represents 1% of Gentex's market cap.

Gentex Shares Remain Undervalued

The market has rewarded Gentex for its consistent profit growth and the stock is up 18% year-to-date. In spite of this price increase, shares remain undervalued. At its current price of \$19/share, GNTX has a price-to-economic book value (PEBV) ratio of 1.1. This ratio means the market expects Gentex's NOPAT to grow by only 10% over the remainder of its corporate life. This expectation seems awfully pessimistic for a firm that has grown NOPAT by 30% a year for the past seven years.


If Gentex can grow NOPAT by 8% compounded annually for the next decade, the stock is worth \$23/share today – a 21% upside. Add in the 1.9% dividend yield and its clear why GNTX was added to this month's Most Attractive Stocks Model Portfolio.

Most Dangerous Stocks Feature: Seneca Foods (SENEA: \$38/share)

Seneca Foods (SENEA), engaged in the packaging of fruit and vegetables, is one of the additions to our <u>Most Dangerous stocks</u> for December.

Seneca Foods' NOPAT has declined from \$69 million in 2012 to 32 million TTM, or -16% compounded annually, per Figure 2

Figure 2: Profit Headed The Wrong Way



Sources: New Constructs, LLC and company filings

Unfortunately for investors in SENEA, the problems don't end with declining NOPAT. The company's ROIC has fallen from 12% in 2009 to a bottom-quintile 3% TTM while its NOPAT margin has fallen from 7% to 2% over the same time.



Impacts of Footnotes Adjustments and Forensic Accounting

In order to derive the <u>true recurring cash flows</u>, an accurate <u>invested capital</u>, and an accurate shareholder value, we made the following adjustments to Seneca Foods' 2016 10-K:

Income Statement: we made \$103 million of adjustments, with a net effect of removing \$19 million in non-operating income (1% of revenue). We removed \$61 million in non-operating income and \$42 million in non-operating expenses. You can see all the adjustments made to SENEA's income statement here.

Balance Sheet: we made \$679 million of adjustments to calculate invested capital with a net increase of \$571 million. One of the largest adjustments was \$167 million due to <u>operating leases</u>. This adjustment represented 34% of reported net assets. You can see all the adjustments made to SENEA's balance sheet <u>here</u>.

Valuation: we made \$595 million of adjustments with a net effect of decreasing shareholder value by \$585 million. Apart from <u>total debt</u>, which includes \$167 million in <u>off-balance-sheet operating leases</u>, the largest adjustment was \$38 million in <u>underfunded pensions</u>. This adjustment represents 10% of Seneca Foods' market cap.

Fundamental Weaknesses Leave SENEA Overvalued

Despite clear deterioration in the fundamentals of the business, SENEA is up 37% year-to-date, which makes shares significantly overvalued. In order to justify its current price of \$38/share, SENEA must grow NOPAT by 5% compounded annually for the next 12 years. This expectation may seem reasonable for a highly profitable company, but SENEA's NOPAT has declined by 16% per year over the last five years.

Even if SENEA can grow NOPAT by 4% compounded annually for the next decade, the stock is only worth \$22/share today – a 42% downside. This scenario assumes SENEA is also able to grow revenue by 5% each year, well above the 1% average over the last five years. Each of these scenarios also assumes SENEA is able to grow NOPAT/free cash flow without spending on working capital or fixed assets. This assumption is unlikely but allows us to create very optimistic scenarios that demonstrate how high expectations in the current valuation are. For reference, SENEA's invested capital has grown on average \$54 million (4% of 2016 revenue) per year over the past decade.

This article originally published here on December 7, 2016.

Disclosure: David Trainer, Kyle Guske II, and Kyle Martone receive no compensation to write about any specific stock, style, or theme.

Scottrade clients get a Free Gold Membership (\$588/yr value) as well as 50% discounts and up to 20 free trades (\$140 value) for signing up to Platinum, Pro or Unlimited memberships. <u>Login or open your Scottrade account</u> & find us under Quotes & Research/Investor Tools.



New Constructs® - Profile

How New Constructs Creates Value for Clients

We find it. You benefit. Cutting-edge technology enables us to scale our <u>forensic accounting</u> <u>expertise</u> across 3000+ stocks. We shine a light in the dark corners of SEC filings so our clients can make safer, more informed decisions.

Our <u>stock rating methodology</u> instantly informs you of the quality of the business and the fairness of the stock's valuation. We do the diligence on earnings quality and valuation so you don't have to.

In-depth risk/reward analysis underpins our ratings. Our rating methodology grades every stock, ETF, and mutual fund according to what we believe are the 5 most important criteria for assessing the quality of an equity. Each grade reflects the balance of potential risk and reward of buying that equity. Our analysis results in the 5 ratings described below. Very Attractive and Attractive correspond to a "Buy" rating, Very Dangerous and Dangerous correspond to a "Sell" rating, while Neutral corresponds to a "Hold" rating.

QUESTION: Why shouldn't fund research be as good as stock research? Why should fund investors rely on backward-looking price trends?

ANSWER: They should not.

Don't judge a fund by its cover. Take a look inside at its holdings and understand the quality of earnings and valuation of the stocks it holds. We enable you to choose the best fund based on its stock-picking merits so you do not have to rely solely on backward-looking technical metrics.

The drivers of our <u>forward-looking fund ratings</u> are Portfolio Management (i.e. the aggregated ratings of its holdings) and Total Annual Costs. The Total Annual Costs Rating (<u>details here</u>) captures the all-in cost of being in a fund over a 3-year holding period, the average period for all fund investors.

Our Philosophy About Research

Accounting data is not designed for equity investors, but for debt investors. Accounting data must be translated into economic earnings to understand the profitability and valuation relevant to equity investors. Respected investors (e.g. Adam Smith, Warren Buffett and Ben Graham) have repeatedly emphasized that accounting results should not be used to value stocks. Economic earnings are what matter because they are:

- 1. Based on the complete set of financial information available.
- 2. Standard for all companies.
- 3. A more accurate representation of the true underlying cash flows of the business.

Additional Information

Incorporated in July 2002, New Constructs is an independent publisher of investment research that provides clients with consulting and research services. We specialize in quality-of-earnings, forensic accounting and discounted cash flow valuation analyses for all U.S. public companies. We translate accounting data from 10Ks into economic financial statements, i.e. NOPAT, Invested Capital, and WACC, to create economic earnings models, which are necessary to understand the true profitability and valuation of companies. Visit the Free Archive to download samples of our research. New Constructs is a BBB accredited business and a member of the Investorside Research Association.



DISCLOSURES

New Constructs®, LLC (together with any subsidiaries and/or affiliates, "New Constructs") is an independent organization with no management ties to the companies it covers. None of the members of New Constructs' management team or the management team of any New Constructs' affiliate holds a seat on the Board of Directors of any of the companies New Constructs covers. New Constructs does not perform any investment or merchant banking functions and does not operate a trading desk.

New Constructs' Stock Ownership Policy prevents any of its employees or managers from engaging in Insider Trading and restricts any trading whereby an employee may exploit inside information regarding our stock research. In addition, employees and managers of the company are bound by a code of ethics that restricts them from purchasing or selling a security that they know or should have known was under consideration for inclusion in a New Constructs report nor may they purchase or sell a security for the first 15 days after New Constructs issues a report on that security.

DISCLAIMERS

The information and opinions presented in this report are provided to you for information purposes only and are not to be used or considered as an offer or solicitation of an offer to buy or sell securities or other financial instruments. New Constructs has not taken any steps to ensure that the securities referred to in this report are suitable for any particular investor and nothing in this report constitutes investment, legal, accounting or tax advice. This report includes general information that does not take into account your individual circumstance, financial situation or needs, nor does it represent a personal recommendation to you. The investments or services contained or referred to in this report may not be suitable for you and it is recommended that you consult an independent investment advisor if you are in doubt about any such investments or investment services.

Information and opinions presented in this report have been obtained or derived from sources believed by New Constructs to be reliable, but New Constructs makes no representation as to their accuracy, authority, usefulness, reliability, timeliness or completeness. New Constructs accepts no liability for loss arising from the use of the information presented in this report, and New Constructs makes no warranty as to results that may be obtained from the information presented in this report. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information and opinions contained in this report reflect a judgment at its original date of publication by New Constructs and are subject to change without notice. New Constructs may have issued, and may in the future issue, other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views and analytical methods of the analysts who prepared them and New Constructs is under no obligation to insure that such other reports are brought to the attention of any recipient of this report.

New Constructs' reports are intended for distribution to its professional and institutional investor customers. Recipients who are not professionals or institutional investor customers of New Constructs should seek the advice of their independent financial advisor prior to making any investment decision or for any necessary explanation of its contents.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would be subject New Constructs to any registration or licensing requirement within such jurisdiction.

This report may provide the addresses of websites. Except to the extent to which the report refers to New Constructs own website material, New Constructs has not reviewed the linked site and takes no responsibility for the content therein. Such address or hyperlink (including addresses or hyperlinks to New Constructs own website material) is provided solely for your convenience and the information and content of the linked site do not in any way form part of this report. Accessing such websites or following such hyperlink through this report shall be at your own risk

All material in this report is the property of, and under copyright, of New Constructs. None of the contents, nor any copy of it, may be altered in any way, copied, or distributed or transmitted to any other party without the prior express written consent of New Constructs. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of New Constructs.

Copyright New Constructs, LLC 2003 through the present date. All rights reserved.